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Introduction {#sec005}
============

*Helicobacter pylori* (*H*. *pylori*) is among the most common pathogenic microorganisms in the world and is involved in the pathogenesis of gastritis, gastroduodenal ulcers, gastric cancer and other diseases\[[@pone.0177455.ref001]\]. At present, *H*. *pylori* eradication therapy for symptomatic patients is universally recognized. A number of prospective cohort studies suggest that *H*. *pylori* eradication is beneficial to patients by preventing the progression of gastric diseases\[[@pone.0177455.ref002], [@pone.0177455.ref003]\]. With the widespread application of eradication therapy, eradication rates have continued to decline steadily over the last decade. However, how to successfully eradicate *H*. *pylori* is still a concern worldwide.

*H*. *pylori* eradication is affected by a number of variables. In addition to host factors, bacteria themselves are also widely believed to play a crucial role, and more research is being conducted on bacterial mutation, biofilm formation, efflux pumps as well as other factors. Additionally, certain virulence factors secreted by *H*. *pylori*, which are helpful in bacterial colonization, induction of inflammation, immune evasion and cancer promotion\[[@pone.0177455.ref004]\], may also affect outcomes of *H*. *pylori* eradication\[[@pone.0177455.ref005]\]. Vacuolating cytotoxin A (*VacA*) and cytotoxin-associated gene A (*CagA*) are two important virulence factors of *H*. *pylori*. *vacA* gene-encoded vacuolating toxins can induce apoptosis, inhibit T-cell activity and avoid clearance by host immunity\[[@pone.0177455.ref006]\]. DNA sequence analysis has revealed that the VacA protein has a mosaic structure comprising allelic variations in the signal (s) and mid region (m), each having two alleles (s1/s2, m1/m2) with different biological activities. The s1 and m1 regions have been associated with peptic ulcer and an increasing risk of gastric cancer\[[@pone.0177455.ref007]\]. Furthermore, some reports noted that *vacA* genotypes have different effects on *H*. *pylori* eradication. For example, Van Doorn et al.\[[@pone.0177455.ref008]\] pointed out that *vacA* s1 strains had higher *H*. *pylori* eradication rates compared with *vacA* s2 strains, but López-Brea et al.\[[@pone.0177455.ref009]\] indicated there was no difference between *vacA* s1 and *vacA* s2 strains. Similarly, for *vacA* m1 and *vacA* m2, Niu et al.\[[@pone.0177455.ref010]\] reported that eradication rates were higher with *vacA* m1 strains. However, Chaudhuri et al.\[[@pone.0177455.ref011]\] drew the opposite conclusion. Another virulence factor closely related to *H*. *pylori* pathogenicity is *cagA*. There is also inconsistency in the relationship between *cagA* and *H*. *pylori* eradication. For example, a literature search\[[@pone.0177455.ref008]\] showed that cure rates in patients infected with *cagA*-positive strains were significantly higher than in patients infected with *cagA*-negative ones, whereas Huang et al.\[[@pone.0177455.ref012]\] came to the opposite conclusion. Studies by Magalhaes et al.\[[@pone.0177455.ref013]\] and Baryshnikova et al.\[[@pone.0177455.ref014]\] showed that *cagA*-positive or *cagA*-negative strains did not affect eradication rates.

Thus, virulence factors *vacA* and *cagA* are not only closely related to pathogenicity but also may be among the main aspects influencing *H*. *pylori* eradication. However, these results remain controversial. Clarification of the correlation between virulence factors and eradication therapy will aid in the rational selection of eradication regimens and in the prediction of eradication outcomes. Therefore, we undertook a systematic review to evaluate the effect of virulence factor *vacA* and *cagA* status on eradication treatment.

Materials and methods {#sec006}
=====================

Identification and eligibility of relevant studies {#sec007}
--------------------------------------------------

Electronic databases of PubMed, Embase, Cochrane Library, Web of Science and Wanfang Data, Chinese National Knowledge Infrastructure (CNKI), China Biology Medicine disc (CBMdisc), and China Science and Technology Jouranl Database (VIP), were systematically searched using the terms, "*vacA*", "*cagA*", "*H*. *pylori*/*Helicobacter pylori*", and "eradication/therapy/treatment". The corresponding Chinese terms were used when searching Chinese databases. Furthermore, references that were cited in each included study were also searched manually to identify potential, additional relevant studies. If the information provided in the article was not sufficiently clear, we contacted the author for detailed raw data. The last search date was October 1, 2016.

Inclusion and exclusion criteria {#sec008}
--------------------------------

Studies included in this meta-analysis must meet the following inclusion criteria: studies published in English or in Chinese; studies investigating the association of *vacA* or *cagA* status for successful eradication of *H*. *pylori* infection; studies with sufficient raw data for estimating RR and their 95% confidence interval (CI). Exclusion criteria: reviews or meta-analyses; animal or cytology experiments; duplicate publications; studies not involving *vacA* or *cagA*; and studies published neither in English nor Chinese; no data of eradication cases to *vacA* or *cagA* status.

Data extraction {#sec009}
---------------

Two authors (Dan Wang and Qiuping Li) extracted the data independently from the included studies. Any conflicts were resolved after discussion, and consensus was finally reached on all extracted data. The following information was extracted from each study: first author, year of publication, country, region, disease, eradication detection method, detection methods for *vacA* and *cagA* status, treatment, therapeutic regimen, and numbers of successful and failed eradications according to *vacA* and *cagA* status.

Quality assessment {#sec010}
------------------

The Newcastle--Ottawa scale (NOS) with eight items was used to estimate the validity of the included studies\[[@pone.0177455.ref015]\]. We evaluated the studies on a nine star scale based on selection (four stars maximum), comparability (two stars maximum) and outcome (three stars maximum). NOS scores of 1--3, 4--6 and 7--9 were considered low, medium and high quality, respectively.

Statistical analysis {#sec011}
--------------------

The statistical analysis was carried out by Stata software (Version 11.0; StataCorp, College Station, TX, USA). The eradication rate was calculated by per-proptocol (PP) analysis. The pooled *H*. *pylori* eradication rates were assessed via a random-effects model. Cumulative RRs and the corresponding 95% CIs were used to measure the strength of associations between the *vacA* or *cagA* status and eradication of *H*. *pylori*. *P* value\<0.05 was considered statistically significant. Heterogeneity across the studies was assessed using a Q statistic (*P*\<0.10 indicates significant heterogeneity between studies) and an I-squared (I^2^) value\[[@pone.0177455.ref016]\].A fixed-effects model using the Mantel--Haenszel method was performed when Heterogeneity between studies was not significant\[[@pone.0177455.ref017]\]. Otherwise, a random-effects model based on the DerSimonian and Laird method was used\[[@pone.0177455.ref018]\]. A sensitivity analysis was performed to explore heterogeneity when significant heterogeneity was indicated. Subgroup analysis was used to explore the effect of region and peptic ulcer disease (PUD) with non-peptic ulcer disease(NPUD), the detection method of eradication, therapeutic regimen. Moreover, publication bias was evaluated quantitatively using Begg's\[[@pone.0177455.ref019]\] and Egger's tests\[[@pone.0177455.ref020]\]. Significant publication bias was indicated if *P* value\<0.05.

Results {#sec012}
=======

Characteristics of the included studies {#sec013}
---------------------------------------

This meta-analysis was organized according to the PRISMA statement ([S1 Table](#pone.0177455.s001){ref-type="supplementary-material"}). A systematic search of Chinese and English electronic databases yielded 1466 citations after removal of duplicates. The flow chart of included studies is summarized in [Fig 1](#pone.0177455.g001){ref-type="fig"}. By screening titles and abstracts, we excluded 1064 citations that were apparently irrelevant, 184 that were reviews or meta-analyses and two that were not full-text articles. After reviewing the full texts of the remaining 216 citations, we removed 125 that were not relevant to this analysis, 30 that were not eradication studies, 24 that were not about *cagA* or *vacA* and 11 that were not clinical trials. Finally, 26 studies that met the inclusion criteria were selected for the meta-analysis. The characteristics of the 26 included prospective studies are presented in [Table 1](#pone.0177455.t001){ref-type="table"}.The NOS results indicated that all the included studies were at an high level of quality with scores ranging from 7 to 8, because some studies did not provide specific selection criteria of control group, some studies only include one kind of gastric disease and most studies did not fully consider the control factor for the comparability of cases and controls such as age and sex. Detailed results for NOS quality assessment were summarized ([S2 Table](#pone.0177455.s002){ref-type="supplementary-material"}).

![Flow chart of literature search and study selection.](pone.0177455.g001){#pone.0177455.g001}

10.1371/journal.pone.0177455.t001

###### Characteristics of selected studies in this meta-analysis.

![](pone.0177455.t001){#pone.0177455.t001g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                                    Year   Country       Region           Disease     Detection method of eradication          Method         Treatment          Therapeutic regimen   Case   Control                               
  ----------------------------------------- ------ ------------- ---------------- ----------- ---------------------------------------- -------------- ------------------ --------------------- ------ --------- -------- ---- ---- -------- ---
  **For *vacA*s1/s2**                                                                                                                                                                                                                       

  López-Brea\[[@pone.0177455.ref009]\]      1999   Spain         South American   NPUD、PUD   Serology、RUT、Histology、Culture、UBT   PCR            BAM,NA             Triple therapy        3      3         0.5000   21   5    0.8077   

  Van Doorn\[[@pone.0177455.ref008]\]       2000   Netherlands   Europen          NPUD、PUD   Histology、RUT、Culture、PCR             PCR            LBTeM,4or5d        Quadruple therapy     56     19        0.7467   11   11   0.5000   

  Rudi\[[@pone.0177455.ref031]\]            2002   Germany       Europen          NPUD、PUD   RUT、PCR、UBT                            PCR            LorO+ACorMC,7d     Triple therapy        80     12        0.8700   19   4    0.8261   

  Scholte\[[@pone.0177455.ref032]\]         2002   Netherlands   Europen          NPUD        Histology、RUT、Culture                  PCR            OAC,7d             Triple therapy        11     0         0.9995   11   2    0.8462   

  He\[[@pone.0177455.ref033]\]              2002   China         Asian            NPUD、PUD   UBT                                      PCR            OAC,7d             Triple therapy        85     19        0.8173   4    2    0.6667   

  Chaudhuri\[[@pone.0177455.ref011]\]       2003   India         Asian            PUD         Histology、RUT、Culture                  PCR            OAC,10d            Triple therapy        26     16        0.6190   2    3    0.4000   

  Russo\[[@pone.0177455.ref030]\]           2003   Italy         Europen          NPUD、PUD   UBT                                      PCR            LAC,7d             Triple therapy        67     20        0.7701   9    12   0.4286   

  De Francesco\[[@pone.0177455.ref021]\]    2004   Italy         Europen          NPUD、PUD   UBT                                      PCR            RA+RTCorRAC,10d    Sequential therapy    40     4         0.9091   46   5    0.9020   

  Niu\[[@pone.0177455.ref010]\]             2014   China         Asian            PUD         Histology、RUT、Cluture、UBT             PCR            LAC,7d             Triple therapy        118    12        0.9077   12   2    0.8571   

  **For *vacA*m1/m2**                                                                                                                                                                                                                       

  Rudi\[[@pone.0177455.ref031]\]            2002   Germary       Europen          NPUD、PUD   UBT、RUT                                 PCR            LorO+ACorMC,7d     Triple therapy        44     5         0.8980   55   11   0.8333   

  Scholte\[[@pone.0177455.ref032]\]         2002   Netherlands   Europen          NPUD        Histology、RUT、Culture                  PCR            OAC,7d             Triple therapy        5      0         0.9995   16   3    0.8421   

  He\[[@pone.0177455.ref033]\]              2002   China         Asian            NPUD、PUD   UBT                                      PCR            OAC,7d             Triple therapy        16     4         0.8000   73   17   0.8111   

  Chaudhuri\[[@pone.0177455.ref011]\]       2003   India         Asian            PUD         Histology、RUT、Culture                  PCR            OAC,10d            Triple therapy        11     13        0.4583   17   6    0.7391   

  **For *vacA*m1/m2**                                                                                                                                                                                                                       

  De Francesco\[[@pone.0177455.ref021]\]    2004   Italy         Europen          NPUD、PUD   UBT                                      PCR            RA+RTCorRAC,10d    Mixed therapy         33     4         0.8919   52   6    0.8966   

  **For *cagA*+/-**                                                                                                                                                                                                                         

  van der Hulst\[[@pone.0177455.ref034]\]   1997   Netherlands   Europe           NPUD、PUD   Histology、Culture                       PCR            OA,14d             Dual therapy          89     33        0.7295   17   16   0.5115   

  Greenberg\[[@pone.0177455.ref035]\]       1999   USA           North America    NPUD        Histology                                WB             OC,14d             Dual therapy          22     12        0.6471   8    0    0.9995   

  López-Brea\[[@pone.0177455.ref009]\]      1999   Spain         Europe           NPUD、PUD   Cerology、RUT、Histology、Culture、UBT   PCR            BAM,NA             Triple therapy        6      2         0.7500   18   6    0.7500   

  Mao\[[@pone.0177455.ref036]\]             2000   Vietnam       Asian            PUD         UBT、Histology                           ELISA          OACorRAC,10d       Triple therapy        78     5         0.9398   19   2    0.9048   

  Van Doorn\[[@pone.0177455.ref008]\]       2000   Netherlands   Europe           NPUD、PUD   Histology、RUT、Culture                  PCR            LBTeM,4or5d        Quadruple therapy     48     11        0.8136   19   19   0.5000   

  Lerro\[[@pone.0177455.ref037]\]           2000   Italy         Europe           NPUD        UBT                                      WB             OAC,14d            Triple therapy        21     14        0.6000   14   1    0.9333   

  Broutet\[[@pone.0177455.ref038]\]         2001   France        Europe           NPUD        UBT、Histology、Culture                  PCR            PAC,NA             Triple therapy        64     20        0.7619   45   27   0.6250   

  Saruc\[[@pone.0177455.ref039]\]           2001   Turkery       Asian            NPUD        Histology、RUT                           ELISA          LAC,7d             Triple therapy        111    16        0.8740   41   16   0.7193   

  Rudi\[[@pone.0177455.ref031]\]            2002   Germany       Europe           NPUD、PUD   RUT、PCR、UBT                            PCR            LorO+ACorMC,7d     Triple therapy        73     9         0.8902   26   7    0.7879   

  Queiroz\[[@pone.0177455.ref040]\]         2002   Brazil        South America    NPUD、PUD   UBT                                      PCR            PFC,7d             Triple therapy        68     7         0.9067   15   5    0.7500   

  Scholte\[[@pone.0177455.ref032]\]         2002   Netherlands   Europe           NPUD        Histology、RUT、Culture                  PCR            OAC,7d             Triple therapy        10     0         0.9995   13   3    0.8125   

  Treiber\[[@pone.0177455.ref029]\]         2002   Germany       Europe           NPUD、PUD   UBT                                      PCR            LorR5d+AMC3dor5d   Quadruple therapy     147    14        0.9130   61   9    0.8714   

  He\[[@pone.0177455.ref033]\]              2002   China         Asian            NPUD、PUD   UBT                                      PCR            0AC,7d             Triple therapy        69     14        0.8313   20   7    0.7407   

  DeFrancesco\[[@pone.0177455.ref041]\]     2002   Italy         Europe           NPUD        UBT                                      ELISA          RA+RTC,10d         Sequential therapy    27     4         0.8710   24   4    0.8571   \

  **For *cagA*+/-**                                                                                                                                                                                                                         

  Chaudhuri\[[@pone.0177455.ref011]\]       2003   India         Asian            PUD         Histology、RUT、Culture                  PCR            OAC,10d            Triple therapy        25     17        0.5952   3    2    0.6000   

  Russo\[[@pone.0177455.ref030]\]           2003   Italy         Europe           NPUD、PUD   UBT                                      PCR            LAC,7d             Triple therapy        69     22        0.7582   8    11   0.4211   

  Xia\[[@pone.0177455.ref042]\]             2003   Australia     Oceania          NPUD        UBT、Histology                           ELISA          OAC,7d             Triple therapy        51     6         0.8947   12   3    0.8000   

  De Francesco\[[@pone.0177455.ref021]\]    2004   Italy         Europe           NPUD、PUD   UBT                                      PCR            RA+RTCor RAC,10d   Mixed therapy         68     5         0.9315   17   5    0.7727   

  Magalhaes\[[@pone.0177455.ref013]\]       2005   Brazil        South America    NPUD、PUD   Histology、RUT                           ELISA          LAC,7d             Triple therapy        30     2         0.9375   25   2    0.9259   

  Jianjun\[[@pone.0177455.ref043]\]         2007   China         Asian            PUD         RUT、Culture                             PCR            EAC,7d             Triple therapy        54     4         0.9310   3    5    0.3750   

  Cen\[[@pone.0177455.ref044]\]             2009   China         Asian            NPUD、PUD   UBT                                      WB             ETCorEAC,7d        Triple therapy        222    27        0.8916   77   19   0.8021   

  Wu\[[@pone.0177455.ref045]\]              2011   China         Asian            NPUD、PUD   UBT                                      Protein chip   EA+AFC,10d         Sequential therapy    23     1         0.9583   95   23   0.8051   

  Huang\[[@pone.0177455.ref012]\]           2012   China         Asian            NPUD        UBT                                      ELISA          LACorLAe,7d        Triple therapy        48     20        0.7059   48   15   0.7619   

  Huang\[[@pone.0177455.ref012]\]           2012   China         Asian            NPUD        UBT                                      ELISA          LACEc,7d           Quadruple therapy     26     4         0.8667   30   3    0.9091   

  Cui\[[@pone.0177455.ref046]\]             2013   China         Asian            NPUD、PUD   UBT                                      Protein chip   EBAZ,7or21d        Quadruple therapy     68     7         0.9067   24   8    0.7500   
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Case:*vacA* s1、*vacA* m1、*cagA*-positve, Contrl:*vacA* s2、*vacA* m2、*cagA*-negative; +: positive,---:negative; NPUD:non peptic ulcer disease, PUD:peptic ulcer disease; UBT:Urea breath test, RUT: rapid urease test assay, PCR:polymerase chain reaction, ELISA:enzyme-linked immuno sorbent assay, WB:western blot; R:rabeprazole, Ra:ranitidine, E:esomeprazole, O:omeprazole,T:tinidazole, C:clarithromycin, A:amoxicillin,B:bismuth,F:furazolidone,Te: tetracycline,Ec:Ecabetsodium,J:josamycin,D:doxycycline.

Association between *vacA* status and eradication of *H*. *pylori* {#sec014}
------------------------------------------------------------------

### *vacA* s1 and *vacA* s2 genotypes and eradication of *H*. *pylori* {#sec015}

Risk ratios regarding the effects of *vacA* s1 and *vacA* s2 genotypes on *H*. *pylori* eradication rates were available for all nine trials, which included data from 772 patients (591 patients in the *vacA* s1 group and 181 patients in *vacA* s2 group). A fixed-effects model was used because significant heterogeneity was not present (I^2^ = 38.4%, *P* = 0.112). The pooled *H*. *pylori* eradication rate was 83% (95%CI: 75--91%) for *vacA* s1 and 73% (95%CI: 61--85%) for *vacA* s2 (Figs [2](#pone.0177455.g002){ref-type="fig"} and [3](#pone.0177455.g003){ref-type="fig"}). We found that eradication rates improved by approximately 10% in the *vacA* s1 group compared with the *vacA* s2 group and that the pooled RR was 1.164 (95%CI: 1.040--1.303, *P* = 0.008; [Table 2](#pone.0177455.t002){ref-type="table"} and [Fig 4](#pone.0177455.g004){ref-type="fig"}). Based on these results, we determined that *vacA* s1 strains are more likely to be eradicated by anti-*H*. *pylori* therapy compared with *vacA* s2 strains.

![The pooled eradication rate of *H*. *pylori* with *vacA* s1.](pone.0177455.g002){#pone.0177455.g002}

![The pooled eradication rate of *H*. *pylori* with *vacA* s2.](pone.0177455.g003){#pone.0177455.g003}

![Forest plot of the association between *vacA* s1 and *vacA* s2 and eradication of *H*. *pylori*.](pone.0177455.g004){#pone.0177455.g004}
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###### Meta-analysis result of the association between *vacA* or *cagA* status and eradication of *H*. *pylori*.

![](pone.0177455.t002){#pone.0177455.t002g}

  Genotype/subgroup   N                    Heterogeneity test   Statistical model   Test for overall effect                                 
  ------------------- -------------------- -------------------- ------------------- ------------------------- --- ------------------------- -------------
  ***vacA*s1/s2**     Overal               9                    38.4                0.112                     F   **1.164(1.040--1.303)**   **0.008**
                      Region                                                                                                                
                      Europe               5                    24                  0.268                     F   **1.203(1.003--1.442)**   **0.046**
                      Asian                3                    59.7                0.042                     R   **1.187(1.028--1.371)**   **0.02**
                      Treatment                                                                                                             
                      Triple therapy       7                    17.6                0.296                     F   **1.175(1.012--1.36)**    **0.035**
  ***vacA*m1/m2**     Overal               5                    28.1                0.235                     F   0.981(0.891--1.081)       0.69
                      Region                                                                                                                
                      Europe               3                    0                   0.676                     F   1.045(0.949--1.151)       0.372
                      Asian                2                    67.9                0.078                     R   0.819(0.508--1.322)       0.414
  ***cagA*+/-**       Overal               25                   56                  \<0.001                   R   **1.094(1.025--1.168)**   **0.007**
                      Region                                                                                                                
                      Europe               11                   66.6                0.001                     R   **1.138(1.000--1.295)**   **0.049**
                      Asian                10                   29.6                0.172                     F   **1.118(1.051--1.190)**   **\<0.001**
                      South America        2                    48.5                0.164                     F   1.104(0.953--1.279)       0.186
                      Disease                                                                                                               
                      NPUD                 9                    69.8                0.001                     R   0.988(0.861--1.134)       0.865
                      PUD                  3                    71.9                0.029                     R   1.274(0.664--2.445)       0.467
                      Method                                                                                                                
                      PCR                  13                   38.9                0.074                     F   **1.232(1.142--1.329)**   **\<0.001**
                      Protein chip         2                    \<0.001             0.885                     F   **1.200(1.060--1.359)**   **0.004**
                      ELISA                7                    \<0.001             0.449                     F   1.048(0.972--1.130)       0.223
                      WB                   3                    89.2                \<0.001                   R   0.801(0.534--1.203)       0.285
                      Treatment                                                                                                             
                      Dual therapy         2                    93                  \<0.001                   R   0.978(0.414--2.307)       0.959
                      Triple therapy       16                   46.4                0.022                     R   **1.090(1.006--1.181)**   **0.034**
                      Quadruple therapy    4                    73.2                0.011                     R   1.134(0.946--1.360)       0.173
                      Sequential therapy   2                    48.2                0.165                     F   1.114(0.997--1.244)       0.057

Next, we conducted subgroup analyses based on region (European or Asian) and therapy regimen (triple therapy). The regional subgroup analysis showed that for Europe and Asia, pooled RRs were 1.203 (95%CI: 1.003--1.442, *P* = 0.046) and 1.187 (95%CI: 1.028--1.371, *P* = 0.020; [Table 2](#pone.0177455.t002){ref-type="table"}), respectively, regarding the effects of *vacA* s1 compared with *vacA* s2 on eradication rates. The therapy regimen subgroup analysis showed that *vacA* s1 status had higher eradication rates in the triple therapy subgroup (RR: 1.175, 95%CI: 1.012--1.360, *P* = 0.035; [Table 2](#pone.0177455.t002){ref-type="table"}).

*vacA* m1 and *vacA* m2 genotypes and eradication of *H*. *pylori* {#sec016}
------------------------------------------------------------------

Risk ratios regarding the effects of *vacA* m1 and *vacA* m2 genotypes on *H*. *pylori* eradication rates were available for all five trials, which included data from 391 patients (135 patients in the *vacA* m1 group and 256 patients in *vacA* m2 group). A fixed-effects model was used because significant heterogeneity was not present (I^2^ = 28.1%, *P* = 0.235). The pooled *H*. *pylori* eradication rate was 84% (95%CI: 71--97%) for *vacA* m1 and 84% (95%CI: 80--89%) for *vacA* m2 (Figs [5](#pone.0177455.g005){ref-type="fig"} and [6](#pone.0177455.g006){ref-type="fig"}). The pooled RR was 0.981 (95%CI: 0.891--1.080, *P* = 0.690; [Table 2](#pone.0177455.t002){ref-type="table"} and [Fig 7](#pone.0177455.g007){ref-type="fig"}). Based on these results, we determined that there was no statistically significant difference in *H*. *pylori* eradication rates between *vacA* m1 and *vacA* m2 genotypes based on therapy. Similarly, subgroup analysis based on region, in European or Asian, indicated that there was no statistically significant difference in *H*. *pylori* eradication rates between *vacA* m1 and *vacA* m2 strains (RR: 1.045, 95%CI: 0.949--1.151, *P* = 0.372; RR: 0.819, 95%CI: 0.508--1.322, *P* = 0.414; [Table 2](#pone.0177455.t002){ref-type="table"}).

![The pooled eradication rate of *H*. *pylori* with *vacA* m1.](pone.0177455.g005){#pone.0177455.g005}

![The pooled eradication rate of *H*. *pylori* with *vacA* m2.](pone.0177455.g006){#pone.0177455.g006}

![Forest plot of the association between *vacA* m1 and *vacA* m2 and eradication of *H*. *pylori*.](pone.0177455.g007){#pone.0177455.g007}

Association between *cagA* status and eradication of *H*. *pylori* {#sec017}
------------------------------------------------------------------

Risk ratios regarding the effects of *cagA*-positive and *cagA*-negative status on *H*. *pylori* eradication rates were available for all 25 trials, which included data from 2693 patients (1793 patients in the *cagA*-positive group and 900 patients in *cagA*-negative group). The pooled *H*. *pylori* eradication rate was 85% (95%CI: 81--89%) for *cagA*-positive and 77% (95%CI: 70--83%) for *cagA*-negative patients (Figs [8](#pone.0177455.g008){ref-type="fig"} and [9](#pone.0177455.g009){ref-type="fig"}). We found that eradication rates were higher by approximately 8% in the *cagA*-positive compared with the *cagA*-negative group and that the pooled RR was 1.094 (95%CI: 1.025--1.168, *P* = 0.007; [Table 2](#pone.0177455.t002){ref-type="table"} and [Fig 10](#pone.0177455.g010){ref-type="fig"}). There was significant heterogeneity that existed among studies (I^2^ = 56.0%, *P*\<0.001). To further investigate the sources of heterogeneity, we conducted a sensitivity analysis. After removing the most obvious outlying study by Van Doorn et al. (RR: 1.63) \[[@pone.0177455.ref008]\], heterogeneity remained (I^2^ = 51.7%, *P* = 0.002). In the remaining studies, using a random-effects model, we still concluded that *cagA*-positive strains had higher *H*. *pylori* therapy eradication rates compared with *cagA*-negative ones (RR: 1.083, 95%CI: 1.017--1.153, *P* = 0.013).

![The pooled eradication rate of *H*. *pylori* with *cagA*-positive.](pone.0177455.g008){#pone.0177455.g008}

![The pooled eradication rate of *H*. *pylori* with *cagA*-negative.](pone.0177455.g009){#pone.0177455.g009}

![Forest plot of the association between *cagA*-positive and *cagA*-negative and eradication of *H*. *pylori*.](pone.0177455.g010){#pone.0177455.g010}

Next, we conducted subgroup analyses based on region (Europe, Asia or South America), disease ((PUD) or NPUD), detection method of eradication (polymerase chain reaction (PCR), protein chip, enzyme-linked immunosorbent assay (ELSIA) or western blot (WB)) and therapeutic regimen (dual-, triple-, quadruple- or sequential therapy). Regional subgroup analysis showed that for Europe and Asia, pooled RRs were 1.138 (95%CI: 1.000--1.295, *P* = 0.049) and 1.118 (95%CI: 1.051--1.190, *P*\<0.001), respectively, regarding the effect of *cagA*-positive compared with *cagA*-negative genotype on eradication. However, in South America, *cagA*-positive strains had similar *H*. *pylori* therapeutic rates compared with *cagA*-negative strains (RR: 1.104, 95%CI: 0.953--1.279, *P* = 0.186; [Table 2](#pone.0177455.t002){ref-type="table"}). Disease subgroup analysis showed that PUD and NPUD subgroups did not improve eradication rates (RR: 1.274, 95%CI: 0.664--2.445, *P* = 0.467; RR: 0.988, 95%CI: 0.861--1.134; *P* = 0.865; [Table 2](#pone.0177455.t002){ref-type="table"}). Subgroup analysis based on the detection method of eradication showed that the *cagA*-positive genotype was associated with higher eradication rates in the PCR and protein chip subgroups (RR: 1.232, 95%CI: 1.142--1.329, *P*\<0.001; RR: 1.200, 95%CI: 1.060--1.359, *P* = 0.004; [Table 2](#pone.0177455.t002){ref-type="table"}) but not in the ELSIA or WB subgroups (RR: 1.048, 95%CI: 0.972--1.130, *P* = 0.223; RR: 0.801, 95%CI: 0.534--1.203, *P* = 0.285; [Table 2](#pone.0177455.t002){ref-type="table"}). Therapeutic regimen subgroup analysis showed that the *cagA*-positive genotype was associated with higher eradication rates in the triple therapy (RR: 1.090, 95%CI: 1.006--1.181, *P* = 0.034) but not in dual- (RR: 0.978, 95%CI: 0.414--2.307, *P* = 0.959), quadruple- (RR: 1.134, 95%CI: 0.946--1.360, *P* = 0.173) or sequential therapy subgroups (RR: 1.114, 95%CI: 0.997--1.244, *P* = 0.057; [Table 2](#pone.0177455.t002){ref-type="table"}).

Publication bias {#sec018}
----------------

We performed the Begg's and Egger's tests to quantitatively evaluate the publication bias of the association between *vacA* and *cagA* for the successful eradication of *H*. *pylori* infection. Publication bias observed in this meta-analysis was not significant. Detailed information for the publication bias test is summarized in [Table 3](#pone.0177455.t003){ref-type="table"}.

10.1371/journal.pone.0177455.t003

###### Publication bias.

![](pone.0177455.t003){#pone.0177455.t003g}

  Genotype          Begg\'s test   Egger\'s           
  ----------------- -------------- ---------- ------- -------
  ***vacA*s1/s2**   1.36           0.175      1.81    0.113
  ***vacA*m1/m2**   0.24           0.806      -1.16   0.33
  ***cagA*+/-**     1.05           0.293      1.45    0.16

Discussion {#sec019}
==========

In this meta-analysis study, the effect of virulence factors *vacA* and *cagA* on eradication treatment was analyzed systematically and the cumulative eradication rates were calculated. Our results showed that the eradication rates in patients infected with *vacA* s1 and s2 strains were 83% and 73%, respectively, for *cagA*-positive, and 85% and 77%, respectively, for *cagA*-negative. Patients with *vacA* s1 and *cagA*-positive strains were more likely to be eradicated, irrespective of *vacA* m subtype. In addition, the correlation of virulence factors with *H*. *pylori* eradication was also affected by factors such as region, detection method of eradication and therapeutic regimen. Our study provides useful information regarding the prediction of eradication outcome and for exploring molecular mechanisms of bacterial resistance.

VacA and CagA are the most intensively studied pathogenic factors of *H*. *pylori*. It is generally accepted that the *vacA* s1 and *cagA*-positive strains are likely more virulent and more closely related with gastric diseases. Our meta-analysis showed that strains carrying more virulence factors were more likely to be eradicated than other strains. We speculated the following reasons for this phenomenon: 1. In patients with a *vacA* s1, *cagA*-positive infection the inflammatory cell infiltration was significantly higher than in those with *vacA* s2, *cagA*-negative \[[@pone.0177455.ref021]\]. On the one hand, inflammatory factors can regulate gastric acid secretion; on the other hand, inflammation-related cytokines can increase local blood flow, which is conducive to antibiotic spread. Changes in gastric acid secretion and improvement in local blood flow can affect the delivery of antibiotics. 2. In patients with a *vacA* s1, *cagA*-positive infection, the permeability of drugs in the gastric mucosa may be significantly higher than in those who were *vacA* s2, *cagA*-negative. *VacA s1*, *cagA*-positive strains can cause more severe mucosal damage, which may allow better penetration of antibiotics from the gastric lumen \[[@pone.0177455.ref022]\] and allow better systemic delivery of drugs \[[@pone.0177455.ref023]\]. 3. One study reported that *H*. *pylori* density is higher and growth is faster in patients with a *vacA* s1, *cagA*-positive infection relative to *vacA* s2, *cagA*-negative patients. In addition, antibiotics have a stronger bactericidal effect during proliferation. 4. *VacA* s1, *cagA*-positive strains promoted synergistic increases in *H*. *pylori* eradication. *VacA* s1 strains have a significant correlation with the presence of *cagA* \[[@pone.0177455.ref007]\]. Most *cagA*-positive strains are *vacA* s1, and *cagA*-negative strains are *vacA* s2. Thus, it is possible that these two factors together improve the eradication effect. 5. Infection with high virulence *H*. *pylori* is more susceptible to bacterial resistance-related gene mutations. For example, some researchers have found that *vacA* s1- and *cagA*-positive strains often contained the A2143G mutation. Such mutations are associated with bacterial clarithromycin resistance \[[@pone.0177455.ref024]\]. In 2006, Suzuki et al.\[[@pone.0177455.ref025]\] performed a meta-analysis to compare the eradication efficacy of CagA-positive and CagA-negative strains in 14 articles. In the present study, we conducted an updated, detailed meta-analysis of 25 published papers to further confirm their study. We also calculated the pooled eradication rate of *H*. *pylori* and evaluated the cumulative RR. Our results indicate that eradication rates were greater by approximately 8% in the *cagA*-positive group compared with the *cagA*-negative group and that the pooled RR was 1.094.

In a further subgroup analysis, the relationship between virulence factor status and eradication efficacy was stratified based on region, disease, detection method of eradication and therapeutic regimen. The results showed that in Europe and Asia, the eradication efficacy was better for *vacA* s1, *cagA*-positive compared with *vacA* s2 *cagA*-negative strains. However, in South America there was no significant difference in the eradication outcome of patients infected with *cagA*-positive or *cagA*-negative strains. These results suggest that in Europe and Asia, patients infected with the *vacA* s1 and *cagA*-positive strains, despite an increased risk of stomach disease, can achieve better eradication rates. In South America, owing to the relatively small number of included studies (n = 1), it cannot be concluded whether *vacA* s1/s2 subtypes were associated with eradication. In the stratified analysis of therapy regimens, *vacA* s1 status had higher eradication rates in the triple-therapy patients. Because of the small number of included studies, we cannot make a comparison between sequential- and quadruple therapy. *cagA*-positive had higher eradication rates in patients who received the triple therapy but not in those who received dual-, quadruple- or sequential therapies. This shows that the efficacy of quadruple or sequential therapy is not affected by *cagA* virulence factors. Perhaps this is one reason why quadruple- or sequential therapy was used more gradually as the first-line treatment than triple therapy. The source of disease analyses showed that neither in the PUD nor in the NPUD subgroups were eradication rates improved regarding *cagA* status, indicating that the relationship between *cagA* and eradication efficacy is not affected by disease status. In addition, when PCR and protein chip methods were used to determine eradication rates, the *cagA*-positive eradication rate was higher than the *cagA*-negative one. However, the same conclusion cannot be reached when the ELISA or WB methods were used. It is possible that compared with the ELISA and WB methods, PCR and protein chip may be more sensitive, reliable and accurate. The traditional ELSIA and WB methods are quantitative assays for detecting serum cagA antibody levels and the results may be affected by various factors. Although the protein chip is also based on the detection of protein, only a small amount of protein sample is needed, because sensitivity is 100 times greater than that of the WB and ELISA, so the results are more reliable and accurate. PCR is a qualitative analysis of the virulence factor at the gene level in gastric mucosal tissues and formalin-embedded specimens. Even if little DNA is contained in these specimens, virulence factors can also be detected using PCR amplification, which can reflect the real situation of gastric infection. In addition, PCR detection also avoids the time-consuming and harsh conditions of *H*. *pylori* culture, so the PCR method will have a broader application in the future.

This meta-analysis had some limitations. First, we only included studies written in English or Chinese. Thus, selection bias might exist. Second, some of individual studies may not result in a tangible conclusion due to PPI brand, type of antibiotic, the small sample size, regional differences, treatment regimen differences, disease background, or differences in detection methods. Therefore, the results from this meta-analysis should be verifiable by conducting a larger and thorough study. Third, the articles on *cagA* and eradication efficacy included two with children as subjects and the remainder with adults. Differences between children and adults may have a potential impact on the eradication efficacy. Fourth, we only analyzed the relationship between *cagA*-positive or negative and eradication efficacy, and did not explore completeness of cag PAI and eradication efficacy. cag PAI is a 40-kb DNA fragment found in the *cagA*-positive strain. The integrity of cag PAI is different in different *H*.*pylori* strains and can be divided into three types: intact-PAI, partially deleted-PAI, and totally deleted-PAI genes. According to the structural differences of cag PAI, *H*. *pylori* can be divided into different virulent groups and cause different clinical outcomes after infection. Because there were few reports regarding differences in integrity of cag PAI and drug resistance, we were unable to perform a meta-analysis on this. In addition, polymorphisms in the EPIYA sequence determine differences in cagA protein function. Based on the EPIYA motifs, *H*. *pylori* was subcategorized as Western or East Asian strains. However, until now there has been no study that has investigated its relationship with eradication efficacy. These unresolved problems are critical in exploring the relationship between virulence factors and eradication efficacy and will be the focus of future research. Fifth, the study of *vacA* and *H*. *pylori* eradication is mainly focused on s and m regions; therefore, a meta-analysis of only these regions was carried out in our study. In fact, polymorphisms of *vacA* mainly include three areas: s, i, and m. However, the relationship between the i region and *H*. *pylori* eradication has been reported to a lesser extent. Only one study has shown that low virulence *vacA* i2 is related to A2143G mutations, and high virulence *vacA* i1 is related to A2142G mutations \[[@pone.0177455.ref026]\], suggesting that there may be some relationship between *vacA* i genotypes and antibiotic resistance. More research is still needed to further validate this correlation. However, the number of such studies is too small to be sufficient for meta-analysis. Sixth, this meta-analysis only summarizes the relationship between virulence factors and drug resistance in patients infected with a single strain. In the included studies used in this meta-analysis, only the one by Russo mentioned two cases of mixed infection of *vacA* s1 and s2, one of which was successfully treated while the other was not. In the rest of the included studies, authors had detected the presence of mixed infections, but they did not analyze the relationship between mixed infection and *H*. *pylori* eradication. Therefore, we cannot further analyze the relationship between mixed infection and eradication efficacy. However, the actual relationship between mixed infection and *H*. *pylori* eradication, and whether it is easier or more difficult to eradicate than a single infection, still requires further research in this area, especially in regions with a high proportion of mixed infections. Seventh, in our included data, the eradication rate was calculated using PP analysis. This method, removing the failed to complete test subjects, will inevitably result in an overestimation of the eradication rates. Because of the small number of studies using intent-to-treat (ITT) analysis, it is not possible to compare the effects of these two analysis programs on eradication rates. Eighth, other virulence factors of *H*. *pylori*, such as *dupA*, *oipA* and *iceA*\[[@pone.0177455.ref027]--[@pone.0177455.ref030]\]may also affect eradication outcomes. However, relatively few of these factors have been reported in the literature, which did not allow us to conduct a systematic meta-analysis of them.

Conclusion {#sec020}
==========

In summary, this meta analysis demostrateded virulence factors *vacA* s1 and *cagA* indeed affect the eradication efficacy of *H*. *pylori*. *vacA* s1, *cagA*-positive strains are easier to eradicate in infected patients, but this has nothing to do with the *vacA* m subtype. In addition, the correlation between *vacA* s1, *cagA*-positive and eradication efficacy was also affected by region, detection method of eradication and therapeutic regimen. Our results suggest that although *vacA* s1 and *cagA*-positive strains are high-risk factors for the development of gastric diseases, the eradication efficacy is better than the other *H*. *pylori* strains. In patients infected with *vacA* s2 and *cagA*-negative strains, though less pathogenic, *H*. *pylori* is more difficult to eradicate. This may be one of the causes of *H*. *pylori* antibiotic resistance. Our study may complement investigations of resistance-related bacterial factors, providing possible clues to further explore *H*. *pylori* antibiotic resistance, which may help in finding a new therapeutic target to eradicate *H*. *pylori*. For all that, the results from our meta-analysis should be verifiable by conducting a larger and thorough study in the further.
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